Marta Torres-Torrillas

Ms. Marta Torres-Torrillas

Bioregenerative Medicine and Applied Surgery Research Group, Department of Animal Medicine and Surgery, University CEU—Cardenal Herrera, CEU Universities, C/Tirant lo Blanc, 7, Alfara del Patriarca, 46115 Valencia, Spain
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MTMarta Torres-Torrillas
Marta Torres-Torrillas
MRMONICA RUBIO
MONICA RUBIO
EGElena Damia gimenez
Elena Damia gimenez
BSBelen Cuervo Serrato
Belen Cuervo Serrato
AMAyla Del Romero Martinez
Ayla Del Romero Martinez
JSJoaquin J. Sopena
Joaquin J. Sopena
Chronic musculoskeletal (MSK) pain is one of the most common medical complaints worldwide and musculoskeletal injuries have an enormous social and economical impact. Current pharmacological and surgical treatments aim to relief pain and restore function; however, unsatiscactory outcomes are commonly reported. In order to find an accurate treatment to such pathologies, over the last years, there has been a significantly increasing interest in cellular therapies, such as adipose-derived mesenchymal stem cells (AMSCs). These cells represent a relatively new strategy in regenerative medicine, with many potential applications, especially regarding MSK disorders, and preclinical and clinical studies have demonstrated their efficacy in muscle, tendon, bone and cartilage regeneration. Nevertheless, several worries about their safety and side effects at long-term remain unsolved. This article aims to review the current state of AMSCs therapy in the treatment of several MSK diseases and their clinical applications in veterinary and human medicine.

19 November 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
PGPAU PELÁEZ GORREA
PAU PELÁEZ GORREA
EGElena Damia gimenez
Elena Damia gimenez
MTMarta Torres-Torrillas
Marta Torres-Torrillas
DCDeborah Chicharro
Deborah Chicharro
BSBelen Cuervo Serrato
Belen Cuervo Serrato
MRMONICA RUBIO
MONICA RUBIO
Osteoarthritis (OA) is the most common articular disease in adults and has a current prevalence of 12% in the population over 65 years old. This chronic disease causes damage to articular cartilage and synovial joints, causing pain and leading to a negative impact on patients’ function, decreasing quality of life. There are many limitations regarding OA conventional therapies—pharmacological therapy can cause gastrointestinal, renal, and cardiac adverse effects, and some of them could even be a threat to life. On the other hand, surgical options, such as microfracture, have been used for the last 20 years, but hyaline cartilage has a limited regeneration capacity. In recent years, the interest in new therapies, such as cell-based and cell-free therapies, has been considerably increasing. The purpose of this review is to describe and compare bioregenerative therapies’ efficacy for OA, with particular emphasis on the use of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP). In OA, these therapies might be an alternative and less invasive treatment than surgery, and a more effective option than conventional therapies.

20 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MVMaría Gemma Velasco
María Gemma Velasco
KSKaty Satué
Katy Satué
DCDeborah Chicharro
Deborah Chicharro
EMEmma Martins
Emma Martins
MTMarta Torres-Torrillas
Marta Torres-Torrillas
MRMONICA RUBIO
MONICA RUBIO
In recent years, several studies have been conducted on Muse cells mainly due to their pluripotency, high tolerance to stress, self-renewal capacity, ability to repair DNA damage and not being tumoral. Additionally, since these stem cells can be isolated from different tissues in the adult organism, obtaining them is not considered an ethical problem, providing an advantage over embryonic stem cells. Regarding their therapeutic potential, few studies have reported clinical applications in the treatment of different diseases, such as aortic aneurysm and chondral injuries in the mouse or acute myocardial infarction in the swine, rabbit, sheep and in humans. This review aims to describe the characterization of Muse cells, show their biological characteristics, explain the differences between Muse cells and mesenchymal stem cells, and present their contribution to the treatment of some diseases.

27 November 2020 in Animals
Verified
Journal Article
Open access
PDF file
AMAyla Del Romero Martinez
Ayla Del Romero Martinez
BSBelen Cuervo Serrato
Belen Cuervo Serrato
PGPAU PELÁEZ GORREA
PAU PELÁEZ GORREA
LMLaura Miguel
Laura Miguel
MTMarta Torres-Torrillas
Marta Torres-Torrillas
MRMONICA RUBIO
MONICA RUBIO
Acute phase proteins (APP) are biomarkers of systemic inflammation, which allow monitoring the evolution of diseases, the response to treatments, and post-operative complications. Ovariectomy (OVE) is frequently performed in veterinary medicine and can be a useful model to evaluate surgical trauma and inflammation in the bitch. The objective was to investigate and compare the acute phase response (APR) after applying three different OVE techniques by measuring serum levels of C-reactive protein (CRP), haptoglobin (Hp), albumin (Alb), and paraoxonase-1 (PON-1). Forty-five intact bitches were included in the study, being randomly distributed into three groups: laparoscopic OVE (L), midline OVE (M), and flank OVE (F). Serum CRP, Hp, Alb, and PON-1 were measured before surgery, 1, 24, 72, and 168 h post-intervention. CRP levels increased significantly 24 h post-surgery in the M and F groups, but no significant variation was observed in the L group at any time of the study period. Hp was significantly higher in group L than in group F 72 h post-surgery. Alb and PON-1 showed no statistical difference among groups or among sampling periods. CRP response suggests that the use of laparoscopic procedures produce lower inflammation compared to open conventional approaches when performing OVE in the bitch.